Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P G Rose

Showing results (121-130 of 125) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 125 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group studyP M Fracasso, M F Brady, D H Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group StudyJ P Curtin, J A Blessing, K D Webster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimensM Markman, P G Rose, E Jones, et al.
Cancer|November 1, 1991
High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancerR E Hunter, T W Griffin, S Stevens, et al.
Gynecologic Oncology|May 17, 2011
Malignant melanoma of the vulva: an extension of cutaneous melanoma?K M Moxley, A N Fader, P G Rose, et al.
Pageof 13

Showing results (121-130 of 125) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 125 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group studyP M Fracasso, M F Brady, D H Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group StudyJ P Curtin, J A Blessing, K D Webster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimensM Markman, P G Rose, E Jones, et al.
Cancer|November 1, 1991
High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancerR E Hunter, T W Griffin, S Stevens, et al.
Gynecologic Oncology|May 17, 2011
Malignant melanoma of the vulva: an extension of cutaneous melanoma?K M Moxley, A N Fader, P G Rose, et al.
Pageof 13